Stem Cell Hunters Capture Their Prey
The human embryonic stem cell, which could be used to grow any other human tissue, has been a stubborn and elusive prey (see “The Troubled Hunt for the Ultimate Cell,” TR July/August 1998). Now, in the scientific equivalent of a photo finish, two teams have announced, in Science and Proceedings of the National Academy of Sciences, respectively, the isolation of stem cells from human embryos. Their results could have very significant implications for biological research and transplant medicine.
The race was complicated by a ban on federal funds for embryo research and opposition from pro-life groups. As a result, funding has come from the private sector. Indeed, both winning groups, one led by James Thomson of the University of Wisconsin, the other by John Gearhart of Johns Hopkins University, had financial backing from Geron Corp., a biotech company in Menlo Park, Calif.
Though the race for the ultimate human cell may be over, the story isn’t. Researchers are likely to tangle for rights to claim the discovery-and patent applications already filed by other teams could complicate the picture.
Keep Reading
Most Popular

Why China is still obsessed with disinfecting everything
Most public health bodies dealing with covid have long since moved on from the idea of surface transmission. China’s didn’t—and that helps it control the narrative about the disease’s origins and danger.

These materials were meant to revolutionize the solar industry. Why hasn’t it happened?
Perovskites are promising, but real-world conditions have held them back.

Anti-aging drugs are being tested as a way to treat covid
Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.

A quick guide to the most important AI law you’ve never heard of
The European Union is planning new legislation aimed at curbing the worst harms associated with artificial intelligence.
Stay connected

Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.